Clinical efficacy of immunotherapy for atopic dermatitis in children

E.A. Kokov¹, N.V. Kolesnikova¹, L.N. Kokova¹, T.M. Andronova<sup>2

1</sup>Kuban State Medical University, Krasnodar
²JSK “Peptek”, Moscow

Aim: to improve clinical efficacy of complex treatment for exacerbations of IgE-mediated atopic dermatitis in children using glucosaminylmuramyl dipeptide (GMPD) — Licopid, immunomodulator of microbial origin.
Patients and Methods: 85 children aged 6–9 years with exacerbations of moderate IgE-mediated atopic dermatitis without clinical manifestations of bacterial, viral, or fungal comorbidities by the time of examination were enrolled in the study. The patients were subdivided into three groups characterized by similar course and area of skin lesions but different treatment strategies. Group 1 (n=30) received complex treatment which included one course of GMPD (Licopid). Group 2 (n=25) received traditional treatment without immunotherapy. Group 3 (n=30) received complex treatment which included two courses of GMPD (Licopid) with a 2-month interval.
Results: complex treatment of exacerbations of IgE-mediated atopic dermatitis using GMPD (Licopid, course dosage 25 mg) reduces the area of skin lesions and the severity of clinical manifestations (subjective signs have totally disappeared after 2 months of the treatment). In addition, two courses of immunotherapy (a total dose of 50 mg) reduces the rate of atopic dermatitis exacerbations and comorbidities more significantly than traditional treatment.
Conclusions: GMPD (Licopid) should be recommended as the first choice drug in the complex immunotherapy due to its clinical efficacy as a part of complex treatment for exacerbations of erythematous squamous and lichenoid IgE-mediated atopic dermatitis with clinical manifestation.

Keywords: atopic dermatitis, traditional treatment, immunotherapy, muramyl peptides, clinical efficacy, glucosaminylmuramyl dipeptide, Licopid.
For citation: Kokov E.A., Kolesnikova N.V., Kokova L.N., Andronova T.M. Clinical efficacy of immunotherapy for atopic dermatitis in children. RMJ. 2019;3:11–14.